8 Esophageal Cancer 1 1 0 7 7 118 http://clinicaltrials.dfhcc.harvard.edu/trials/118 Proton Radiotherapy With Chemotherapy for Nasopharyngeal Carcinoma Photon beam radiation is the standard type of radiation used to treat nasopharyngeal carcinoma. Photon beam radiation enters the body and passes through healthy tissue, encounters the tumor and leaves the body through healthy tissue. Proton beam radiation has been shown to have the same effect on tumors as photon beam radiation but it enters the body, passes through healthy tissue, and encounters the tumor but then stops. This means less healthy tissue is affected by proton beam treatment than by photon beam treatment. The purpose of this study is to determine the effectiveness of proton beam radiation in treating nasopharyngeal cancer and reducing the acute and long-term side effects from the treatment. This study will also test to see if the sparing of the healthy tissue can improve quality of life Recruiting 8 Esophageal Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/8-esophageal-cancer 9 Head and Neck Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/9-head-and-neck-cancer Phase 2 204 http://clinicaltrials.dfhcc.harvard.edu/trials/204 Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer There is no clear standard of care for metastatic stomach or esophageal cancer in the United States. The purpose of this research study is to determine the differences between two regimens of chemotherapy; Arm A: PCA (Cisplatin, Irinotecan and Bevacizumab) and Arm B: TPCA (Docetaxel, Cisplatin, Irinotecan and Bevacizumab). Docetaxel, Cisplatin, and Irinotecan are traditional chemotherapy drugs. Bevacizumab is an antibody (a protein that attacks a foreign substance in the body). Bevacizumab is believed to stop the formation of new blood vessels that carry nutrients to tumors. Both of the chemotherapy regimens (PCA and TPCA) have been studied in patients with esophageal and gastric cancer, and we are trying to determine if one regimen will keep your cancer from growing and improve how long you can live. Recruiting 26 Stomach Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/26-stomach-cancer 8 Esophageal Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/8-esophageal-cancer Phase 2 1057 http://clinicaltrials.dfhcc.harvard.edu/trials/1057 Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma A pilot study to determine the safety of using perioperative panitumumab with EOX in patients with adenocarcinoma of the esophagus and stomach. Recruiting 26 Stomach Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/26-stomach-cancer 8 Esophageal Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/8-esophageal-cancer Phase 1/Phase 2 96 http://clinicaltrials.dfhcc.harvard.edu/trials/96 Prospective Analysis of Hypersensitivity Reactions to Oxaliplatin This research study will examine how often hypersensitivity, or allergic reactions, occur in patients receiving the chemotherapy medication oxaliplatin. Hypersensitivity reactions can vary from a transient skin rash and fever to more severe symptoms such as shortness of breath, chest tightness, and a more severe allergic reaction that can affect blood pressure called anaphylaxis. We will be examining how often hypersensitivity reactions occur and how severe the reactions are when they occur. We will also examine whether there are factors that place people at risk for developing hypersensitivity reactions to oxaliplatin. In an optional portion to this study, we will examine whether allergy skin testing can predict whether someone will develop a hypersensitivity reaction. Participants who develop a moderate to severe allergic reaction to oxaliplatin will be invited to participate in an additional portion of the study examining a desensitization process. This part of the study will examine whether a desensitization process can prevent future hypersensitivity reactions to oxaliplatin in patients who previously developed moderate to severe hypersensitivity reactions and allow therapy with oxaliplatin to continue. Recruiting 19 Pancreatic Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/19-pancreatic-cancer 26 Stomach Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/26-stomach-cancer 8 Esophageal Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/8-esophageal-cancer 5 Colorectal Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/5-colorectal-cancer 12 Liver Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/12-liver-cancer N/A 242 http://clinicaltrials.dfhcc.harvard.edu/trials/242 Preliminary Longitudinal Validation of Biomarkers Predictive of Barrett's Esophagus Barrett's esophagus can progress to esophageal cancer, but it doesn't always. Current treatment is frequent surveillance via upper endoscopy with multiple biopsies to look for changes (dysplasia). Pathologists vary dramatically in their interpretation of Barrett's Metaplasia versus dysplasia and consensus is very difficult to achieve. The investigators propose a longitudinal study of subjects with confirmed Barrett's intestinal metaplasia without dysplasia to look for predictive factors for transformation to dysplasia or cancer. Potential biomarkers can be found in serum, plasma, urine, frozen or fixed Barrett's and Normal esophageal mucosa. In addition, the investigators are testing a brushing technique from CDx, Inc. for predictive factors. Subjects must have pathologically confirmed Barrett's intestinal metaplasia without history of dysplasia to be on this longitudinal study. Recruiting 8 Esophageal Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/8-esophageal-cancer N/A 1223 http://clinicaltrials.dfhcc.harvard.edu/trials/1223 Phase II Trial of BIBW 2992 in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification. The primary objective of this trial is to estimate the objective response rate for patients with tumors harbouring EGFR and/or HER2 gene amplifications or EGFR activating mutations who will be treated with BIBW 2992. Recruiting 1 Bladder Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/1-bladder-cancer 18 Ovarian Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/18-ovarian-cancer 8 Esophageal Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/8-esophageal-cancer 7 Endometrial/Uterine Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/7-endometrial-uterine-cancer 1233 http://clinicaltrials.dfhcc.harvard.edu/trials/1233 Vandetanib, Oxaliplatin, and Docetaxel in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction RATIONALE: Vandetanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as oxaliplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether vandetanib is more effective than a placebo when given together with oxaliplatin and docetaxel in treating advanced cancer of the esophagus or gastroesophageal junction. PURPOSE: This randomized phase I/II trial is studying the side effects and best dose of vandetanib when given together with oxaliplatin and docetaxel and to see how well it works in treating patients with advanced cancer of the esophagus or gastroesophageal junction. Recruiting 8 Esophageal Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/8-esophageal-cancer